An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 4, 1998, Pages 416-419

  Ohtsu, Atsushi ^a   Boku, Narikazu ^a   Tamura, Fumio ^a   Muro, Kei ^a   Shimada, Yasuhiro ^b   Saigenji, Katsunori ^c   Akazawa, Shugo ^d   Kitajima, Masaki ^e   Kanamaru, Ryunosuke ^f   Taguchi, Tetsuo ^g  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

^g Japan Soc for Cancer Chemotherapy   (Japan)

Author keywords

Gastric cancer; Paclitaxel; Phase II study

Indexed keywords

CISPLATIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS;

EID: 0031819130     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199808000-00021     Document Type: Article

References (17)

1. Wani MC, Taylor HL, Wall ME, et al. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
2. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
3. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12.
4. McGuire WP, Rowinsky EK, Rosenstein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian neoplasms. Ann Intern Med 1989;111:273-9.
5. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
6. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
7. Shiller JH, Storer B, Tutsch K, et al. Phase I trial of 3 h infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-8.
8. Klaassen U, Diergarten K, Dittrich C, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis. Onkologie 1994;17:86-90.
9. Eisenhauer EA, Huinink WW, Awenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
10. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotention just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 1995;86:1203-9.
11. Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clinical Cancer Research 1996;2:941-5.
12. Ajani JA, Ilson DH, Daugherty K, Padzur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
13. Einzig AI, Lipsitz S, Wiernik PH, Benson III AB. Phase II trial of taxol in patients with adenocarcinoma of the upper GI tract (UGIT). Invest New Drugs 1995;13:223-7.
14. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. Journal of Japanese Society for Cancer Research 1993;28:101-30.
15. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English ed. Tokyo: Kaneharasyuppan, 1995.
16. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-51.
17. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanism of action and resistance [Review]. J Natl Cancer Inst Monographs 1993;15:55-61.